Global Conjunctivitis Treatment Market - 2022-2029

Global Conjunctivitis Treatment Market - 2022-2029

Market Overview

The Conjunctivitis Treatment market was valued at USD 3,750.60 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 3.88% during the forecast period (2022-2029).

Conjunctivitis is a common condition that causes redness and inflammation of the thin layer of tissue that covers the front of the eye. It can be highly contagious. But it’s rarely serious. It's very unlikely to damage the vision. Conjunctivitis caused by some bacteria and viruses can spread easily from person to person, but it isn’t a serious health risk if diagnosed promptly. If it happens in a newborn baby, though, tell a doctor right away, as it might be an infection that threatens the baby’s vision.

Allergies are also a common cause of conjunctivitis. The cells in the conjunctiva can react to an allergen. Some examples of allergens include grass, dust, animal fur, and mascara. Both viral and bacterial conjunctivitis can occur along with colds or symptoms of a respiratory infection, such as a sore throat. Other symptoms of conjunctivitis include itchiness and watering of the eyes, and sometimes a sticky coating on the eyelashes.

Conjunctivitis caused by Chlamydia trachomatis or Neisseria gonorrhoeae requires aggressive antibiotic therapy, but conjunctivitis due to other bacteria is usually self-limited. Chronic conjunctivitis is usually associated with blepharitis, recurrent styes, or meibomianitis. Treatment requires good eyelid hygiene and the application of topical antibiotics as determined by culture. Allergic conjunctivitis is distinguished by severe itching and allergen exposure.

Market Dynamics

The market is driven is the increasing prevalence of conjunctivitis in developing countries is one of the factors driving the global market during the forecast period. The surge in the prevalence of sexually transmitted diseases (STDs) is another factor likely to propel the global market during the forecast period. Factors such as poor hygiene conditions, premature deliveries, and maternal sexually transmitted infection are some of the risk factors for neonatal conjunctivitis. Lack of awareness about the treatment of the disease in developing countries and lack of coverage of medicines in these countries are some of the factors restraining the global neonatal conjunctivitis treatment market during the forecast period.

The market is also driven by rising air pollution in major cities across the globe. According to the world bank published in 2021, Air pollution is responsible for health costs of around 8.1 trillion US$, equivalent to 6.1 percent of the global GDP. Some earlier research studies have proven that ambient air pollution can aggravate conjunctivitis and allergic conjunctivitis. This is attributed to the conjunctiva being sensitive to environmental particles along with direct contact of the conjunctiva with the outside environment. Hence, the rise in air pollution propels the global conjunctivitis treatment market.

Professor C. Michael Gibson M.S., M.D, has published Conjunctivitis epidemiology and demographics, in 2020, viral conjunctivitis commonly affects adults, and bacterial conjunctivitis affects children. The incidence of infective conjunctivitis is higher in children less than 1-year-old (8,000 cases per 100,000 patients) than in children less than 4 years of age (1,200 cases per 100,000 patients). The disease is very common, and treatment for the same is easily available. Most of the time, the disease is self-diagnosable, and there is least need to undergo any diagnostic test for this disease.

Countries like India are also having a high prevalence of conjunctivitis. For instance, on 2nd February 2020, Tamil Nadu state notified that viral conjunctivitis problem among the student and staff in school.

A rise in awareness among people about the disease and its treatment is also boosting the market. Several states are actively promoting the treatment of the disease. Easy availability of the treatment is boosting the market. The rise in disposable income is also driving the growth of the market in the forecast period.

However, the market is expecting to face a patent cliff in the coming years. The availability of certain cost-effective generic medicines is likely to hamper the market growth extensively. The scarcity of novel compounds available for preclinical and clinical examination is affecting the growth of the market. The dearth of investigations regarding approval of drugs and bacterial conjunctivitis in the pipeline is affecting the market growth in the forecast period.

Moreover, the outbreak of the COVID-19 pandemic across the globe is set to negatively impact the global market growth. Despite the patients suffering from conjunctivitis tend to be at a high risk of getting injected by viral conjunctiva that is usually caused because of adenovirus, the market is expected to undergo a decline. While coronavirus also causes several similar ocular signs and symptoms, such as conjunctivitis infection, watery discharge, photophobia, and eye irritation.

Due to the stringent lockdowns imposed by governments across the globe, the postponement or cancellations of non-life-threatening medical visits is expected to restrict the market growth as lesser prescriptions for conjunctivitis will be issued in this period. This factor will hamper the market growth in the forecast period.

Market Segmentation:

The global conjunctivitis treatment market is segmented based on disease type into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment held the largest market share. Allergic conjunctivitis is common and causes sudden swelling in the eyelids and ocular itching. People having allergies are more likely to develop allergic conjunctivitis.

As stated by the Asthma and Allergy Foundation of America, approximately 30% of adults and 40% of children suffer from allergies in the United States. The diagnosis of the disease is usually done by self. However, if someone is unable to identify the disease, there are certain tests that the doctor performs to understand the disease and its cause. Some of the tests include allergy skin tests, a blood test to see if the patient's body is producing proteins, or antibodies, to protect itself against specific allergens like mold or dust. This factor will drive the growth of the market in the forecast period.

Moreover, the National Institutes of Health (NIH) indicated that the number of patients being diagnosed with allergic conjunctivitis is increasing globally. This increase in incidence rate propels the global allergic conjunctivitis treatment market. Pharmaceutical companies are developing new treatment options for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC’s EM-100 is currently in phase 3 of a clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two-third of new treatment options are in phase 2 or 3 of clinical trials. All these studies are being sponsored by major pharmaceutical companies. These factors are driving the growth of the market in the forecast period.

The bacterial conjunctivitis segment is expected to have positive market growth in the forecast period. Bacterial conjunctivitis is one of the major eye problems encountered worldwide and are caused by bacteria such as Moraxella and Chlamydia trachomatis. These bacteria are responsible for causing persistent conjunctivitis with a higher level of redness. Most of the cases of bacterial conjunctivitis are acute and self-limiting and not a major cause of serious health problems however, due to its high prevalence the infection can have a large impact on society as individuals tend to miss their school or work.

The increasing cases of bacterial conjunctivitis demand efficient medication, which supports the growth of the bacterial conjunctivitis drugs market. Bacterial conjunctivitis spreads because of poor hygiene, immune compromise, and ocular diseases such as dry eye, blepharitis, and contaminated cosmetics. It can be prevented by maintaining proper hygiene and also hand wash reduces the chances of bacterial conjunctivitis. This factor will drive the growth of the market in the forecast period.

Further, the market is also classified based on drug class as antibiotics, ophthalmic steroids, non-steroidal anti-inflammatory drugs (NSAIDS), antihistamines, others. The antibiotics segment is held the largest market share. Antibiotics may help shorten the length of infection, reduce complications, and reduce the spread to others. Antibiotics may be necessary for people whose immune system is compromised. In certain cases where an underlying infection elsewhere in the body may be causing conjunctivitis symptoms, you may be prescribed antibiotics to swallow in tablet form. Standard antibiotic treatments often will work for ordinary bacterial infections related to staphylococcus (staph) or streptococcus (strep) infections, which are the usual causes of bacterial conjunctivitis in adults. This factor will drive the growth of the market in the forecast period.

Typical antibiotic treatment often will work for these types of bacterial infections without the need to swab the eye and send off a sample (culture) for evaluation. If the initial treatment doesn't work, then a culture may be needed so that treatment can be changed to a more specialized type of antibiotic.

Geographical Presentation

By region, the conjunctivitis treatment market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global conjunctivitis treatment market and is expected to grow at the highest CAGR during the forecast period due to the presence of a large number of key players operating in the conjunctivitis treatment market.

According to the National Institute of Health that conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer. Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share in the forecast period. According to the Asthma and Allergy Foundation of America, more than 50 million people experienced with various types of allergies in every year. In the 50 million people, estimated approximately around 6.5 million people that acute conjunctivitis affects in the United States. These factors are expected to fuel the overall market growth across the region.

The Asia-Pacific region is expected to have the third-largest share due to an increase in the prevalence of infections, poor hygiene conditions in developing countries, and prolonged deliveries in some of the countries in the region. Furthermore, the booming medical tourism industry in countries such as India, China, and Malaysia are expected to boost demand for the treatment. These factors stimulate market growth over the forecasted period in the region.

Competitive Landscape:

The conjunctivitis treatment market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Boehringer Ingelheim GmbH, Allergan Inc., Sanofi-Aventis, Novartis AG, Bausch & Lomb Inc., CIBA Vision Ophthalmic, Pfizer Inc., Merck & Co., Inc., and Santen Pharmaceuticals Co. Ltd. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the conjunctivitis treatment market across the globe.

For instance, On 25th February 2021, Allergan, an AbbVie company, submitted its new drug application for investigational AGN-190584 for the Treatment of Presbyopia. The most common treatment-emergent non-serious adverse events occurring at a frequency of ≥5% in AGN-190584 treated participants were headache and conjunctival hyperemia.

On 30th June 2022, Novartis acquired the Kedalion Therapeutics AcuStream platform, a topical ocular delivery device used to facilitate dosing support and the delivery of front-of-eye therapies.